Is endometrial monitoring required with the use of long-term unopposed vaginal estrogen?

Climacteric

Volumn 9, Issue 5, 2006, Pages 321-322

  MacLennan, Alastair H ^a   Sturdee, David W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN;

CANCER GRADING; CANCER INVASION; CANCER RISK; CURETTAGE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FALSE POSITIVE RESULT; FEMALE; HUMAN; HYSTEROSCOPY; INCIDENCE; MONITORING; MORBIDITY; MORTALITY; POSTMENOPAUSE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERUS BLEEDING;

ADMINISTRATION, INTRAVAGINAL; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGENS; FEMALE; HUMANS; MASS SCREENING;

EID: 33749039660     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130600955229     Document Type: Editorial

References (5)

1. Smith DC, Prentice R, Thompsom DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-9
2. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD001500. DOI: 10.1002/14651858.CD001500
3. Crandall C. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. J Women's Health 2002;11:857-77
4. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92
5. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485